The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A....
-
Upload
neil-mcdaniel -
Category
Documents
-
view
215 -
download
2
Transcript of The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A....
![Page 1: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/1.jpg)
The Use of the Hemobag®
to Improve Clinical Outcomes in
any Blood Management Program
Keith A. Samolyk CCP, LCPGlobal Blood Resources LLC
WWW.MYBLOODFIRST.COMWWW.MYBLOODFIRST.COM
![Page 2: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/2.jpg)
2
Roadmap
Factors affecting transfusion decisions
Blood conservation techniques
Ways to reverse hemodilution
Ultrafiltration / Hemoconcentration
The Hemobag® – how it works
Clinical trial of the Hemobag® Flagship cases
![Page 3: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/3.jpg)
3
What drives transfusion decisions?
6,980 CABG patients
Significant association:
Hctlowest & death
IABP & return to CPB
No association:
Hctlowest and stroke
NNECDSG 1998
Surgeon (56%)
Patient Variables (35%)
Disease Variables (9%)
Age, sex, BSA, comorbidity score
LVEDP, EF, LM stenosis, # diseased vessels, lowest Hct on CPB vs. adverse outcomes
![Page 4: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/4.jpg)
4
Lowest Hct on CPB vs Adverse Outcomes6,980 CABG patients
Significant association
Hctlowest & death
IABP & return to CPB
No association
Hctlowest & stroke
0
1
2
3
4
5
<19 19-20 21-22 23-24 >25
Lowest Hct on CPB
Ad
just
ed M
ort
alit
y
NNECDSG(Defoe 2000)
![Page 5: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/5.jpg)
5
Managing anemia with transfusion after CPB increases mortality
10,178 CABG patients
If Hct < 22% & raised with transfusion...
Mortality directly Mortality directly influenced by influenced by transfusiontransfusion
0
1
2
3
4
5
6
7
8
<22 22-24 24-26 >26
<21>21
NNECDSG
![Page 6: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/6.jpg)
6
During ECC18- 21% { normal risk patients } 21- 25% { high-risk patients during bypass }
Post-OperativelyAdequate oxygen delivery decreases morbidity & mortality22-25% { normal risk patients }25-30% { high-risk patients }
Jehovah's Witness patients Remarkable tolerance of severe acute normovolemic anemia
Tight adherence to specific guideline
Most cases can be performed without using allogeneic bloodwithout using allogeneic blood and a HCT above min.
Minimum Accepted Hematocrit Levels
![Page 7: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/7.jpg)
7
Typical Blood Conservation Techniques Used Today
Acute Normovolemic Hemodilution (ANH)
Hemodilution with crystalloid solutions
Intraoperative Autologous Donation (IAD)
Cell Saver for Shed Blood and Conservation
Apheresis / Platelet Gel / PRP
Ultrafiltration (Hemoconcentration), HemobagUltrafiltration (Hemoconcentration), Hemobag®®
Autotransfusion of unprocessed Shed Blood
from chest tube collection drains
![Page 8: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/8.jpg)
8
Blood Conservation Techniques for ECCMinimize circuit prime by
Condensing circuit to accommodate priming volume of ~1100 mL – 1400 mL
Smaller volume increases risk of micro-air, poor air handling qualities, and less reaction time
Retrograde Autologous Prime (RAP)***Displace crystalloid prime with patients own whole bloodpatients own whole blood
slow controlled exsanguination (1000 mL or more) team support of Anesthesia short acting vasoconstrictors like Neosynepherine
Can be done for freefree and is very cost effective
Closed Biocompatible/Heparin Coated Systems/SMC Reduce surface activation of bloodAir is foreign surface
![Page 9: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/9.jpg)
9
Total Body Water Increase leads to:Total Body Water Increase leads to:Tissue edema & cellular/organ dysfunction
Prolonged ventilatory support
Pulmonary hypertension
Decreased lung compliance
Coagulopathy
Anesthesia may give 1-4 L perioperatively For every 1L of crystalloid given only 250 mL remain intravascular
It’s not just ECC that contributes to hemodilutionIt’s not just ECC that contributes to hemodilution
![Page 10: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/10.jpg)
10
Average Circuit Volume is ~ 1200–1600mL
Retrograde Auto Priming for free canreduce circuit prime volume to ~ 500–800 mL or less
while maintaining a safe and trusted circuit
helping to eliminate hemodilution hemodilution
How else can we reverse HemodilutionHow else can we reverse Hemodilution ? ?
![Page 11: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/11.jpg)
11
Answer:Answer: Hemoconcentraters Hemoconcentraters
![Page 12: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/12.jpg)
12
Positive Effects of Ultrafiltration/Hemoconcentration
Removes noncellular H20
Decreases total body H20 concentrating WB
Increases Hctplatelets & clotting factorsalbumin & plasma proteins
Removes cytokines & anaphylatoxins
C3a, C5aIL6, IL8, TNF-AET-1, bradykininsadhesion moleculessE-Selectin
Improves organ fcnmyocardial fcn
cerebral oxygenation
pulmonary compliance
Reduces post-op blood loss
reduces transfusions
Reduces perioperative morbidity
Naik, 1991, Hospital for the Sick, Great Ormond St. UK
![Page 13: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/13.jpg)
13
Benefits of MUFMUF increases
Post CPB Hct
Systolic and diastolic pressure
Cardiac Index
Myocardial contractility
Red cell mass
Pulmonary compliance
Arterial oxygenation
Cerebral oxygenation
Left ventricular function
Diastolic compliance
Plasma proteins
![Page 14: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/14.jpg)
14
Heart rate & PVR
Myocardial wall thickness
Pulmonary hypertension
Incidence of effusions
Intrapulmonary shunt fraction
24 hr blood loss
Inotrope requirement
Blood product usage
TBW content
Hospital stay
Ultrafiltration combats Hemodilution
MUF decreases
![Page 15: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/15.jpg)
15
How does it happen?
![Page 16: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/16.jpg)
16
![Page 17: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/17.jpg)
17
Permeability varies with type of capillary
Capillary type varies with organ function
1. Tight (brain) 2. Continuous (skeletal muscle, skin) 3. Fenestrated (secretory glands, kidney, gut) 4. Discontinuous (liver, spleen, bone marrow)
Capillary "Type"
![Page 18: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/18.jpg)
18
Edema:Edema: Most common clinical manifestation of
an imbalance of forces at the capillary wall Excess accumulation of fluid in the interstitial space that has not
been readsorbed into capillaries or taken up by the lymphatics
Causes includeObstruction Permeability or change in reflection coefficient
Increased protein permeability results in an imbalance Occurs in trauma, thermal injury, inflammationLife threatening manifestations - endotoxic shock, ARDS
Plasma ProteinReduction in circulating plasma proteins, especially albuminLiver dysfunction, malnutrition, or acute alteration of fluid status
Albumin attenuates extravasation of fluid out of intravascular space to interstitial space
Capillary pressure
![Page 19: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/19.jpg)
19
![Page 20: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/20.jpg)
20
How can we get these positive effects of HEMOCONCENTRATIONHEMOCONCENTRATION?
Naik, 1991, Hospital for the Sick, Great Ormond St. UK
Removes noncellular H20
Decreases total body H20
concentrating WB
Increases Hct
Platelets & clotting factors
Albumin & plasma proteins
Removes cytokines & anaphylatoxins
Improves organ fcnmyocardial fcn
cerebral oxygenation
pulmonary complianceReduces post-op blood loss reduces transfusions
Reduces perioperative morbidity
![Page 21: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/21.jpg)
A New Technology for Blood Management is the
HEMOBAGHEMOBAG®®
A Universal Blood Reservoir for
Salvaging Autologous Whole Blood
from ECC’s
• Specially designed for quickly– Filling– Hemoconcentrating–Transfusing – All in the same Hemobag®
• Doubles use of any Hemoconcentrator
![Page 22: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/22.jpg)
22
TS3 Tubing Set doubles the use of any Hemoconcentrator
For use both during the case
![Page 23: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/23.jpg)
23
And at the end of the case forWhole Blood Salvaging of the ECC Circuit
![Page 24: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/24.jpg)
24
HEMOBAG® SUMMARYHEMOBAG® SUMMARY
![Page 25: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/25.jpg)
25“Your Body Your Choice” pg. 26, S.Farmer and D. Webb
![Page 26: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/26.jpg)
26
The Big Picture
Choices/ Alternatives Publication Vol 4 Issue 2, Center for Bloodless Medicine and Surgery, University of Miami / Jackson Med Ctr.
![Page 27: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/27.jpg)
27
Salvaged Blood with a Cell Saver
![Page 28: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/28.jpg)
28
Blood Salvaged with the Hemobag®
Everything that’s Autologous is Concentrated and given back for stability and Homeostasis
![Page 29: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/29.jpg)
29
21.4
53.1
2.68.2 92
305.8
186
266
1 2 3 4 Hct % Total Protein g/dl Fibrinogen mg/dl Platelet Count K/ul
Pre- and Post- Hemobag Blood Components
Pre-Hemobag
Post-Hemobag
Average change in blood parameters:
Pre-Hemobag Post-HemobagHCT 21.4% 53.1%Total Protein 2.6 g/dL 8.2 g/dL Fibrinogen 92 mg/dL 305.8 mg/dLPlatelet Conc. 186 K/uL 266 K/uL
Data from 40 Patients’ ECCs
chased with 2.0 L of crystalloid filling the Hemobag®
Salem Hospital, Salem Oregon
Ave. volume returned = 820 mL
Average time toFill the Hemobag®: 60 sec +/- 20 sec
Hemoconcentrate contents of the Hemobag® (2L1L):
10.5 min +/- 1 min (total = 11.5 min +/- 80 sec)
![Page 30: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/30.jpg)
30
155
364
221
740
2357
0
100
200
300
400
500
600
700
800
Plt. Ct. k/cumm Fibrinogen mg/dl HCT %
Change in Blood Parameters
Patient Hemobag
0
5
10
15
Change in Protein Levels
Patient 2.3 4
Hemobag 6.6 11.7
Albumin gm/dl Total Protein gm/dl
Results represent what is possible with the
Hemobag®
FLAGSHIP CASE #1:FLAGSHIP CASE #1:Over 80y/o female, AVR case, post-op bleeding: 300mL, left ICU post-op Day #1, no blood products given
Reinfused 900 mL Conc. 900 mL Conc. Autologous Whole BloodAutologous Whole Blood from CPB circuit with:
Hct = 57%
Platelets = 364 K
Fibrinogen = 740 mg
Albumin = 6.6 g/dL
Total protein = 11.7 g/dL
Time: 12 minutes
Extracorporeal circuit kept viable & ready to go back emergently
![Page 31: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/31.jpg)
31
241
430292
972
26 56
0
200
400
600
800
1000
Plt. Ct. k/cumm Fibrinogen mg/dl HCT %
Change in Blood Parameters
Patient Hemobag
0
5
10
15
Change in Protein Levels
Patient 2.1 4.1
Hemobag 5.7 13.6
Albumin gm/dl Total Protein gm/dl
FLAGSHIP CASE #2:FLAGSHIP CASE #2:60 yr old CABG x 3, post-op bleeding was 290 mL, left ICU on Post-op Day #1, no blood products given
Reinfused 1150 mL Conc. 1150 mL Conc. Autologous Whole BloodAutologous Whole Blood from CPB circuit with:
Hct = 56%
Platelets = 430 K
Fibrinogen = 972 mg
Albumin = 5.7 g/dL
Total protein = 13.6 g/dL
300% increase in FVII
73% activity to 223%
Time: 10 minutes
Extracorporeal circuit kept viable & ready to go back
Illustrates capabilities of the
Hemobag® when used for Whole Blood Salvaging in CV Surgery
![Page 32: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/32.jpg)
32
Both the Hemobag® and TS3 tubing set come 5 to a box and are sold together
![Page 33: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/33.jpg)
33
Sterile Peel Pouches
![Page 34: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/34.jpg)
34
Easy to Understand Directions
![Page 35: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/35.jpg)
35
Benefits Overview
CELL SAVER HEMOBAG®
If you were the patient wouldn’t you want all your own AUTOLOGOUS CELLS back first?
VS
![Page 36: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/36.jpg)
36
Conclusion about the Hemobag®
The Hemobag® system effectively Concentrates Extracorporeal Circuit contents Produces Autologous Whole Blood
high in RBC’s and plasma proteins
Offers advantages over current technology quick, easy, enhanced end product
“The Hemobag® is the Missing Piece in the Big Picture of
Blood Salvaging and Conservation”
![Page 37: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/37.jpg)
37
Bottom Line Life is related to blood and anything you can do to save more of a patient’s Own Whole Blood is better than anything else … Period !
Patients transfused with allogeneic blood products are exposed to a host of new potential complications
No one is exempt from resultant immunosuppression
The least of these is a mild form of TRALI which leads tolonger and delayed time to extubation & discharge from the ICU
increased risk of Morbidity and Mortality
Autologous whole blood is jugular for perfect natural homeostasis
We should be doing everything we can to conserve more of this precious substance
It’s in the Patient’s Best Interest - It’s the Right of all Patients
![Page 38: The Use of the Hemobag ® to Improve Clinical Outcomes in any Blood Management Program Keith A. Samolyk CCP, LCP Global Blood Resources LLC.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649e9f5503460f94ba11ec/html5/thumbnails/38.jpg)
38
Thank You for listening !Global Blood Resources LLC
WWW.MYBLOODFIRST.COM WWW.HEMOBAG.COM